Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
— Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC — — Exscientia’s A2A biomarker signature...

Sydney Thunder Keep Unchanged Squad for WBBL Clash Against Perth Scorchers
Command Discipline Takes Precedence as Home Ministry Suspends Delhi ACP Manasvi Vashishta
Karnataka High Court Quashes BJP Slogan FIR, Ads Case, Sets 24-Hour Custody Rule
Tamil Nadu Government Allows Six Daily Film Shows Starting at 6 AM
Ranji Trophy: How Nagwaswalla, Gaja, and Patel Put Gujarat in Control Against Kerala 





























